Infliximab, adalimumab and golimumab for the second line treatment of moderately to severely active ulcerative colitis (including review of TA140 and TA262)
 
Status Complete
Process MTA
Topic area
  • Digestive system

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance